Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression

Addition of the CCR5 inhibitor Maraviroc (MVC) to ongoing antiretroviral therapy increases CD4+ T cell counts in some virologically suppressed patients with suboptimal CD4+ T cell recovery. To understand the mechanisms by which MVC elicits increases in CD4+ T cell counts, the present study was under...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Beliakova-Bethell, Nadejda, Jain, Sonia, Woelk, Christopher H., Witt, Mallory D., Sun, Xiaoying, Lada, Steven M., Spina, Celsa A., Goicoechea, Miguel, Rought, Steffney E., Haubrich, Richard, Dubé, Michael P.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4116489/
https://ncbi.nlm.nih.gov/pubmed/24769244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2014.04.005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars